Favorable Treatment Outcome in Non-Hodgkin's Lymphoma Patients with "Poor" Mobilization of Peripheral Blood Progenitor Cells

Keith E. Stockerl-Goldstein, Sunil A. Reddy, Sandra J. Horning, Karl G. Blume, Nelson J. Chao, Wendy W. Hu, Laura J. Johnston, Gwynn D. Long, Samuel Strober, Ruby M. Wong, Robert H. Feiner, Sabine Kohler, Robert S. Negrin

Research output: Contribution to journalArticlepeer-review

60 Scopus citations


Our purpose was to evaluate the outcome and costs of high-dose chemotherapy and autologous peripheral blood progenitor cell (PBPC) transplantation in patients with the inability to mobilize sufficient numbers of PBPCs to allow rapid engraftment after PBPC transplantation. We treated 172 consecutive non-Hodgkin's lymphoma (NHL) patients with cyclophosphamide and granulocyte colony-stimulating factor followed by apheresis to collect PBPCs. The cells were separated on a Percoll gradient and purged with monoclonal antibodies and complement. The patients were categorized as "good" mobilizers if a collection of ≥2 × 106 CD34+ cells/kg was obtained (n = 138, 80%) or "poor" mobilizers if <2 × 106 CD34+ cells/kg were obtained (n = 34, 20%). With a median follow-up of 3.5 years, there is no statistically significant difference in actuarial event-free survival, overall survival, or relapse for good mobilizers compared with poor mobilizers. However, there was a trend toward increasing nonrelapse, transplantation-related mortality of 11.8% for poor mobilizers versus 3.6% for good mobilizers (P = .08) and early death from all causes including relapse within 120 days (poor 20.6% versus good 8.7%, P = .06). The total cost for bone marrow transplantation-related care was significantly higher, at $140,264 for poor mobilizers versus $80.833 for good mobilizers (P = .0001). The population of patients with NHL who mobilize PBPCs poorly into the circulation have a higher cost for posttransplant support. However, there is no significant difference in relapse, event-free survival, or overall survival for such patients compared with those who mobilize PBPCs easily.

Original languageEnglish
Pages (from-to)506-512
Number of pages7
JournalBiology of Blood and Marrow Transplantation
Issue number5
StatePublished - 2000


  • Autologous transplantation
  • Non-Hodgkin's lymphoma
  • Regimen toxicity


Dive into the research topics of 'Favorable Treatment Outcome in Non-Hodgkin's Lymphoma Patients with "Poor" Mobilization of Peripheral Blood Progenitor Cells'. Together they form a unique fingerprint.

Cite this